Related by context. All words. (Click for frequent words.) 83 Phase Ib clinical 79 phase Ib 78 phase IIa clinical 78 Phase Ib study 78 Phase Ib 77 Phase IIIb clinical 77 Cloretazine ® 76 phase IIb 76 rALLy clinical trial 76 multicenter Phase II 76 alvespimycin 76 phase IIb clinical 76 BRIM2 76 phase IIb trial 75 Phase 1b 75 phase Ib clinical 75 multicenter Phase 75 dose escalation clinical 75 BRIM3 75 LUX Lung 75 Phase 1b clinical 75 phase IIa 74 PSMA ADC 74 mertansine 74 Phase IIb III 74 Phase #b/#a 74 Phase #b/#a clinical 74 dose escalation trial 74 Phase 1b trial 74 Pivotal Phase III 73 dose escalation Phase 73 neratinib 73 blinded randomized placebo controlled 73 Phase 1a clinical 73 initiated Phase Ib 73 HGS# 73 ADVANCE PD 73 FOLOTYN ® 73 Phase 2a trial 73 CHAMPION PCI 73 Prostate AdenoCarcinoma Treatment 73 Panzem R NCD 73 ongoing Phase 1b 73 placebo controlled Phase III 73 SUCCEED trial 73 Omacetaxine 72 deforolimus 72 forodesine 72 placebo controlled Phase 72 Phase IIB 72 Quinamed 72 Phase 2b study 72 Bayer HealthCare Onyx Pharmaceuticals 72 Phase Ia 72 Phase III randomized controlled 72 enzastaurin 72 Phase #/#a 72 evaluating tivozanib 72 fosbretabulin 72 Phase IIb trials 72 randomized controlled Phase 72 Phase 2a clinical 72 randomized Phase III 72 trastuzumab DM1 T DM1 72 randomized Phase 2b 72 Aplidin 72 pertuzumab 72 Phase 2b trial 72 YONDELIS 72 NO# [002] 72 Phase III 72 Phase III Pivotal 72 Phase IIIb 72 APEX PD 72 Phase Ib IIa 71 pivotal bioequivalence 71 Phase III Clinical Trials 71 Phase 1a 71 tramiprosate Alzhemed TM 71 sunitinib malate 71 Phase 1b clinical trials 71 elotuzumab 71 Initiate Phase 71 Phase 2a 71 Phase IIa clinical 71 TASKi2 71 Combination REOLYSIN R 71 Cloretazine 71 multicenter randomized Phase 71 oral ridaforolimus 71 Alocrest 71 pharmacokinetic PK study 71 ENDEAVOR IV 71 Phase IIb clinical trials 71 initiate Phase IIb 71 NSABP B 71 Sapacitabine 71 PI3K/Akt pathway inhibitor 71 Phase IIb clinical 71 phase 2a 71 INCB# [001] 71 Enzastaurin 71 CBLC# 71 tesmilifene 71 phase IIb study 71 HGS ETR1 71 Phase III Clinical Trial 71 IMC A# 71 Phase III psoriasis 71 huN# DM1 71 TG MV 71 BCIRG 71 Aflibercept 71 multicenter randomized placebo controlled 71 confirmatory clinical 71 Aplidin R 70 Initiates Phase II 70 multicenter phase 70 Phase III ThermoDox 70 phase IIIb 70 AEG# 70 Exherin TM 70 Deforolimus 70 IMPACT IMmunotherapy 70 Pivotal Trial 70 receptor tyrosine kinase inhibitor 70 Phase lll 70 PDX pralatrexate 70 midstage clinical 70 HuMax EGFr 70 Triapine R 70 MAGE A3 ASCI 70 cathepsin K inhibitor 70 CRMD# 70 HDAC Inhibitor 70 adecatumumab 70 galiximab 70 Initiated Phase 70 registrational 70 ganetespib 70 assessing T DM1 70 Phase IIa trials 70 Amrubicin 70 PEG SN# 70 Phase 2b clinical 70 IMA# 70 relapsed MM 70 oral deforolimus 70 IMC #B 70 PANVAC VF 70 acyclovir Lauriad R 70 VNP#M 70 Phase IIb 70 SinuNase ™ 70 MGd 70 Phase IIa trial 70 CAMMS# 70 Randomized Phase II 70 Cloretazine R VNP#M 70 Immunotherapeutic 70 ixabepilone 70 CALGB # [002] 70 ENESTnd 70 Completes Patient Enrollment 70 randomized controlled multicenter 70 Archexin 70 multicentre randomized 70 APTIVUS 70 docetaxel Taxotere R 70 adecatumumab MT# 69 depsipeptide 69 candidate CRLX# 69 Phase III HEAT 69 Successfully Completes Phase 69 ELACYT 69 IL# PE#QQR 69 registrational Phase 69 Xelox 69 Allovectin 7 69 IIa clinical 69 Myocet 69 HCV SPRINT 69 IIa trial 69 treatment naive genotype 69 AVN# Phase 69 XL# SAR# 69 Initiates Phase III 69 Phase III pivotal 69 oral prodrug 69 Phase 2b Clinical Trial 69 Vitaxin 69 axitinib 69 budesonide foam 69 multicenter Phase III 69 Phase II 69 trastuzumab emtansine T DM1 69 CRLX# 69 Tarceva TM 69 ABSORB clinical 69 Hsp# Inhibitor 69 evaluating satraplatin 69 AKT inhibitor 69 HGS ETR2 69 CEQ# 69 GLP toxicology studies 69 AEGR 69 Blinatumomab 69 Pivotal Study 69 fidaxomicin Phase 69 lintuzumab 69 Phase III TRIST 69 OMP #M# 69 non nucleoside inhibitor 69 PRT# 69 ZACTIMA 69 ThermoDox R 69 relapsed refractory multiple myeloma 69 including eniluracil ADH 69 ENDEAVOR III 69 seliciclib CYC# 69 preclinical efficacy 69 JAK inhibitor 69 RE SURGE 69 antibody MAb 69 phase IIb III 69 Dacogen injection 69 ARRY # 69 multicenter clinical 69 Phase 2b randomized 69 AQ4N 69 EXPLORE Xa 69 Phase III clinical 69 Pivotal Phase 69 Phase 2b clinical trials 69 Phase IIA 69 Phase III placebo controlled 69 Phase 2b monotherapy 69 lead Aganocide compound 69 sorafenib Nexavar 69 PDE4 inhibitor 69 teriflunomide 69 ToGA 69 Phase III multicenter 69 Annamycin 69 investigational protease inhibitor 69 CALGB 69 initiate Phase 1b 69 Ceflatonin R 69 Ozarelix 69 IMPACT DCM 69 vidofludimus 68 PFO migraine 68 MOZOBIL 68 Plicera 68 biliary tract cancer 68 crizotinib PF # 68 BR.# 68 GetGoal Phase III 68 Phase 2b 68 Pazopanib 68 PSN# [002] 68 Trastuzumab DM1 68 PF # [002] 68 GW# [003] 68 Clinical Trial Results 68 pharmacokinetic PK 68 farletuzumab 68 STRIDE PD 68 dose cohorts 68 telomerase inhibitor drug 68 CR# vcMMAE 68 PRTX 68 Phase 2b kidney transplant 68 huC# DM4 68 Tesmilifene 68 Proellex TM 68 placebo controlled clinical 68 OvaRex R 68 ATL# [001] 68 HCV RESPOND 2 68 Androxal TM 68 novel VDA molecule 68 ENMD # 68 ZK EPO 68 OvaRex ® MAb 68 lorvotuzumab mertansine 68 metastatic hormone refractory 68 RE LY ® 68 Zenvia Phase III 68 TransVax TM 68 LUMINATE 68 multicenter randomized controlled 68 Hedgehog Pathway Inhibitor 68 EchoCRT 68 Degarelix 68 randomized Phase IIb 68 dose cohort 68 Tarvacin TM 68 Cloretazine R 68 CVac 68 initiate Phase Ib 68 ThermoDox ® clinical 68 Azedra 68 RGB # 68 recurrent malignant glioma 68 bevirimat Study 68 evaluating Actimmune 68 HuLuc# 68 confirmatory Phase III 68 Phase IIb trial 68 riociguat 68 Targretin capsules 68 HCD# [002] 68 Sym# 68 AVOREN 68 Omnitarg 68 mapatumumab 68 registrational trial 68 Shigamabs ® 68 cilengitide 68 Initiates Enrollment 68 Randomized Phase 68 fidaxomicin Phase 3 68 nucleotide analog 68 Phase IIB clinical 68 evaluating mipomersen 68 investigational humanized monoclonal antibody 68 APPRAISE 68 TKB# 68 Initiates Clinical Trial 68 initiate multicenter 68 GRNVAC1 68 TBC# 68 Curaxin CBLC# 68 fostamatinib 68 BrachySil TM 68 viral kinetic 68 MEND CABG 68 Aurora kinase inhibitor 68 Medullary Thyroid Cancer 68 paclitaxel poliglumex 68 Initiates Clinical 68 Vicriviroc 68 lintuzumab SGN 68 GVAX ® 68 Nasdaq IDRA today 68 double blinded placebo 68 Sigma Tau SpA 68 Phase IIb Clinical Trial 68 bapineuzumab AAB 68 NABTT 68 Elagolix 68 CLL8 68 CLARITY study 67 eprotirome 67 Tesetaxel 67 CLORETAZINE TM VNP#M 67 imetelstat GRN#L 67 Glufosfamide 67 Fludara ® 67 Phase 2a clinical trials 67 Pralatrexate 67 trastuzumab DM1 67 evaluating Xcytrin 67 MKC# MKC# PP 67 Initiate Phase II 67 Zemplar Capsules 67 ChronVac C R 67 Velcade bortezomib 67 Pertuzumab 67 sorafenib Nexavar ® 67 IIb clinical trial 67 double blinded randomized 67 romidepsin 67 NOX E# 67 RSD# oral 67 SAR# [004] 67 MIVI III 67 unique alkylating agent 67 rALLy trial 67 LymphoStat B TM 67 NVA# 67 EOquin TM 67 ANCHOR trial 67 Phase IIa 67 CYT# potent vascular disrupting 67 relapsed multiple myeloma 67 rindopepimut 67 treatment naïve genotype 67 oral antiviral 67 Personalized Immunotherapy 67 midstage trials 67 MEND CABG II 67 Meets Primary Endpoint 67 dose escalation 67 Pafuramidine 67 DermaVir Patch 67 SPRYCEL ® 67 bevacizumab Avastin ® 67 PXD# 67 Urocidin 67 nab paclitaxel 67 SUTENT ® 67 TMC# C# 67 lorcaserin Phase 67 sapacitabine 67 Lenocta 67 IND submission 67 ALSYMPCA 67 Phase III Trial 67 Tykerb lapatinib 67 lumiliximab 67 AP# [003] 67 ospemifene 67 MERLIN TIMI 67 LibiGel Phase III 67 Safinamide 67 Urocortin 2 67 Phase IIb Trial 67 Allovectin 7 R 67 liposomal formulation 67 BLA filing 67 telomerase therapeutic 67 Phase IIIb study 67 REVIVE Diabetes 67 MKC# MT 67 trodusquemine 67 Bezielle 67 RH1 67 phase III ACCLAIM 67 YONDELIS R 67 OncoVex 67 PROSTVAC TM 67 ONCONASE R 67 SABCS 67 dose escalation phase 67 Cethrin R 67 Matrix Phase 2b 67 Achieves Primary Endpoint 67 eritoran 67 Erbitux cetuximab 67 Commences Phase 67 recurrent glioblastoma multiforme 67 EGFR HER2 67 PRECISE trial 67 PrevOnco 67 Afatinib 67 reslizumab 67 FOLFOX6 chemotherapy regimen 67 VESTASYNC 67 pivotal Phase III 67 ExTRACT TIMI 67 eniluracil 67 prospective multicentre 67 XL# XL# XL# 67 ara C 67 BAY #-# 67 Xanafide 67 Virulizin ® 67 BiTE R 67 DIRECT Trial 67 Phase 1b dose escalation 67 Antiviral Activity 67 EndoTAG TM -1 67 Daclizumab 67 II Clinical Trial 67 HER2 positive metastatic breast 67 Carfilzomib 67 randomized multicenter Phase III 67 pharmacodynamic PD 67 Panzem NCD 67 Brentuximab Vedotin SGN 67 nucleoside analog 67 DASISION 67 PRESEPT 67 MT#/MEDI-# 67 pharmacokinetics PK 67 paclitaxel Taxol R 67 Phase III confirmatory 67 randomized Phase 67 SNT MC# 67 PEP# [003] 67 Proxinium TM 67 erlotinib Tarceva ® 67 Phase 2b Study 67 brivaracetam 67 PREOS R 67 talabostat 67 Nexavar sorafenib 67 refractory chronic lymphocytic 67 tanespimycin 67 Multiple Ascending Dose 67 Pharmacokinetics PK 67 PROSTVAC VF 66 Allovectin 7 ® 66 apricitabine ATC 66 Phase Ib clinical trials 66 velafermin 66 TMC# [002] 66 Phase Ib Clinical Trial 66 Temsirolimus 66 Ceflatonin 66 ENGAGE AF TIMI 66 subcutaneous formulation 66 Panzem ® 66 Alzhemed TM 66 CD# CEA 66 ZYBRESTAT TM 66 bortezomib Velcade 66 preclinically 66 PHX# 66 CUSTOM III 66 Phase 2b Trial 66 Maximum Tolerated Dose MTD 66 TAXUS ATLAS 66 OncoVEX GM CSF 66 dosing cohort 66 metastatic castration resistant 66 tolerated dose MTD 66 Dose Ranging Study 66 CA9 SCAN 66 PROSTASCINT R 66 CoFactor 66 Dapagliflozin 66 HuMax CD4 66 DSMB recommended 66 Augment Injectable 66 NP2 Enkephalin 66 TG# [001] 66 Motesanib 66 paclitaxel Taxol ® 66 PRIMO CABG 66 Xeloda ® 66 3 registrational trial 66 SCH # 66 ACOMPLIA R 66 dacetuzumab 66 TLK# 66 vinca alkaloid 66 apricitabine 66 anticancer compound 66 TASKi3 66 Telatinib 66 REG2 66 sapacitabine CYC# 66 ICON7 66 Phase III randomized 66 oral picoplatin 66 Silodosin 66 Kahalalide F 66 European Sepsis Trial 66 investigational HCV polymerase 66 cediranib 66 virus HCV protease inhibitor 66 GLPG# 66 OLpur TM H2H 66 Nasdaq PGNX today 66 R#/MEM # 66 tubulin inhibitor 66 Presents Preclinical 66 Phase III ADT 66 DU #b 66 Pivotal Phase II 66 maximally tolerated dose 66 PROTECT AF 66 TACI Ig 66 zanolimumab 66 RELOVAIR ™ 66 Bicifadine 66 Genasense ® 66 docetaxel Taxotere ® 66 brivanib 66 NCCTG 66 vascular disrupting agent 66 Tyrima 66 ORACLE MS 66 BRAF inhibitor 66 OPT CHF 66 PF # [001] 66 EXPAREL ™ 66 ZYBRESTAT fosbretabulin 66 ritonavir boosted 66 Fx #A 66 Vectibix panitumumab 66 metaglidasen 66 Multicenter Phase 66 Cethromycin 66 Exelixis XL# 66 telaprevir VX 66 Harry Palmin President 66 Oral Fingolimod 66 Reports Preclinical Data 66 R sorafenib tablets 66 Medidur TM FA 66 novel histone deacetylase 66 evaluating REVLIMID 66 Hormone Refractory Prostate Cancer 66 OXi# 66 Phase III registrational 66 velafermin belinostat 66 BioNumerik 66 Acute Decompensated Heart Failure 66 Chemophase 66 initiate Phase 2b 66 Begins Dosing 66 immunotherapeutic agent 66 Teriflunomide 66 Apaziquone 66 viral kinetics 66 FOLFIRI chemotherapy 66 CURE AF 66 THALOMID 66 Phase III Psoriasis 66 glufosfamide 66 dasatinib Sprycel 66 PROSTVAC ® 66 davunetide intranasal AL 66 Dalbavancin 66 Hepatocellular Carcinoma HCC 66 perifosine KRX 66 interferon gamma 1b 66 EVEREST II 66 rNAPc2 66 ascending dose 66 Severe Sepsis 66 histone deacetylase HDAC inhibitor 66 Romidepsin 66 dexanabinol 66 obatoclax 66 NPC 1C 66 GRAVITAS trial 66 elacytarabine 66 ORAL Sync 66 lomitapide 66 antibody blinatumomab MT#/MEDI-# 66 inhaled AAT 66 Neulasta R 66 CCR5 antagonist 66 Prospective Randomized 66 Presents Positive 66 Phase III metastatic melanoma 66 EMPHASIS HF trial 66 docetaxel Taxotere 66 multicenter randomized Phase III 66 sorafenib tablets 66 UPLYSO 66 metastatic HRPC 66 CA4P 66 Ultrafast Insulin 66 lexidronam injection 66 INSPIRE Trial Phase III 66 thalidomide Thalomid 66 Estybon ™ 66 mitogen activated ERK kinase 66 OncoGel 66 Mipomersen 66 ancrod 66 MEK inhibitor 66 Civacir 66 Pivotal Clinical Trial 66 PEG IFN 66 torezolid phosphate 66 Trofex 66 isavuconazole 66 SAR# [002] 66 ACAPODENE 66 goserelin 66 Presents Preclinical Data 66 EFAPROXYN 66 apoptosis inducer 66 standard chemotherapy regimen 66 non nucleoside HCV 66 clevidipine 65 indibulin 65 lapatinib Tykerb 65 OMP #R# 65 MGCD# [001] 65 evaluating T DM1 65 Cetrorelix 65 demonstrated antitumor activity 65 UVIDEM 65 bendamustine 65 GAMMAGARD 65 vemurafenib 65 ROCKET AF 65 AAG geldanamycin analog 65 albiglutide 65 CCX# B 65 relapsing remitting MS RRMS 65 dosing cohorts 65 PERSEUS 65 NXL# 65 metastatic castrate resistant 65 BCR ABL inhibitor 65 leading oral taxane 65 ProLindac 65 Novolimus 65 teduglutide 65 Randomized Evaluation 65 Pemetrexed 65 5 fluorouracil leucovorin 65 JAK2 Inhibitor 65 generation purine nucleoside 65 STEALTH C 65 Elvitegravir 65 MVA MUC1 IL2 65 oral proteasome inhibitor 65 solithromycin 65 bortezomib Velcade R 65 bardoxolone 65 hypoxia activated prodrug 65 CELVAPAN H#N# 65 EURIDIS 65 Investigational Compound 65 palifosfamide Zymafos TM 65 Nexavar ® 65 celgosivir 65 PEARL SC 65 CTAP# Capsules 65 Study Evaluating 65 HORIZONS AMI 65 ularitide 65 HCV polymerase 65 PrevOnco ™ 65 BrachySil ™ 65 pomalidomide 65 satraplatin Phase 65 Onconase 65 Neulasta ® 65 Triapine 65 Xeloda capecitabine 65 XL# XL# 65 dasatinib Sprycel ® 65 CD# monoclonal antibody 65 Nanobody 65 Dose Escalation 65 AERAS-#/Crucell Ad# 65 Traficet EN 65 TransVax ™ 65 PEGylated interferon beta 1a 65 histamine dihydrochloride 65 controlled multicenter Phase 65 omacetaxine mepesuccinate 65 Microplasmin 65 Ambrisentan 65 Troxatyl 65 clinical pharmacology studies 65 DEB# 65 ChronVac C ® 65 Actilon 65 PRE SURGE 65 confirmatory Phase 3 65 ILLUMINATE 65 selective orally bioavailable 65 dose escalation study 65 AVADO 65 Aryplase 65 p# biomarker 65 Diabetic Macular Edema 65 ritonavir boosted danoprevir 65 aflibercept VEGF Trap 65 Folfox 65 CYT# 65 Phase 2a Clinical Trial 65 AVAX 65 aflibercept 65 Parathyroid Hormone 65 Kinase Inhibitor 65 ONTARGET 65 tremelimumab 65 BiTE antibody MT# 65 please visit www.advaxis.com 65 AZILECT R 65 MEK Inhibitor 65 oral rivaroxaban 65 MORAb 65 Genasense oblimersen sodium Injection 65 compound INCB# 65 atacicept 65 GRN# 65 Factor VIIa 65 MAA submission 65 amrubicin 65 Exherin 65 prospective multicenter 65 pan HDAC inhibitor 65 AVERROES 65 evaluating carfilzomib 65 Pivotal Trials 65 TRO# 65 Ocrelizumab 65 Presents Positive Preclinical 65 IgG1 monoclonal antibody 65 Fodosine 65 Protease Inhibitor 65 Phase Ia Ib 65 multi kinase inhibitor 65 docetaxel chemotherapy 65 pain palliation 65 randomized multicenter 65 telaprevir dosed 65 CAMPATH 65 GALNS 65 recurrent NSCLC 65 Ixempra 65 vinorelbine tartrate 65 Phase #/#a trial 65 randomized discontinuation trial 65 ALN VSP Phase 65 APEX AMI trial 65 initiated Phase 1b 65 alemtuzumab Campath 65 LibiGel ® 65 Ridaforolimus 65 Panzem R 65 Zalypsis 65 RE LY 65 gefitinib Iressa 65 GMX# 65 darinaparsin ZIO 65 multicenter placebo controlled 65 EDEMA3 65 L BLP# 65 Zenvia ™ 65 Insulin PH# 65 Vascular Disrupting Agent 65 GATTEX TM 65 MabThera rituximab 65 trial evaluating PRX# 65 VITAL Trial 65 SPIRIT FIRST 65 KRN# 65 orally administered inhibitor 65 Acute Ischemic Stroke 65 opioid induced bowel dysfunction 65 ATAC Arimidex Tamoxifen Alone 65 AIMM trial 65 Cetrorelix pamoate 65 Oral Calcitonin 65 vosaroxin 65 #I TM# 65 plus Copegus R 65 Zerenex ™ 65 Clolar ® 65 aurora kinase 65 MEK inhibitor RDEA# 65 IMPACT DCM clinical 65 Vicinium TM 65 Tanespimycin 65 PCI ExTRACT TIMI 65 Cardiotoxicity 65 Pharmacokinetic Study 65 Testosterone MDTS ® 65 LEVADEX ™ 65 COU AA 65 ENDEAVOR II 65 Thiovir 65 palifosfamide 65 angiogenesis inhibitor 65 human IgG1 monoclonal 65 XL# XL# XL# XL# 65 PKC# 65 generation URAT1 inhibitor 65 Prodarsan 65 PNP inhibitor 65 Raptiva R 65 TNFerade TM 65 Systemic Delivery 65 doxorubicin Transdrug ® 65 COSIRA trial 65 StemEx 65 Febuxostat 65 Phase #/#a clinical 65 immunotherapeutic vaccine 65 Pharmacodynamic 65 Pimavanserin 65 ZOLINZA 65 estramustine 65 Pre RELAX AHF 65 Novel Oral 65 oncolytic vaccine 65 optimal dosing regimen 65 Phase III ALLEGRO 65 NCIC CTG 65 ANTEGREN 65 IAP inhibitors 65 Elotuzumab 65 dalbavancin 65 evaluating Prochymal 65 Neoadjuvant 65 Imprime PGG 65 Renal Cell Carcinoma RCC 65 StemEx R 65 cobiprostone 65 Randomized Double Blind 65 Phase #b/#a trial 65 acyclovir Lauriad ® 65 multiple ascending dose 65 thorough QT 65 Stimuvax R 65 Irinotecan 65 TOCOSOL Camptothecin 65 bevacizumab Avastin 65 Taxotere ® 65 rALLy 65 EORTC 65 investigational monoclonal antibody 65 TRA 2P 65 entinostat 65 thymalfasin 65 IMP# 65 EndoTAG 65 TELINTRA 65 CALERIE 65 Viprinex TM 65 Vaxfectin TM 65 Laquinimod 65 oncolytic virus therapies 65 beta 1a 65 Dasatinib 65 IIa trials 64 LEUKINE 64 ofatumumab HuMax CD# 64 Golimumab 64 Catena ® 64 CIMZIA ™ 64 GENASIS 64 IMiDs R 64 TEMSO 64 Kamada AAT 64 epigenetic therapies 64 Prolongs Survival 64 Genasense ® oblimersen 64 RhuDex ® 64 Asentar 64 Corlux 64 ABSORB trial 64 Darinaparsin 64 ZD# [001] 64 Pirfenidone 64 oral salmon calcitonin 64 cetuximab Erbitux R 64 regorafenib 64 REG1 Anticoagulation System 64 RenalGuard System TM 64 Solazed 64 Multicenter Randomized 64 GVAX R 64 pralatrexate injection folate analogue 64 Nasdaq HALO 64 Deferiprone 64 chemotherapy FOLFOX 64 nucleotide analogue 64 kidney urologic 64 trastuzumab Herceptin R 64 pivotal Phase 64 Phase III VISTA 64 LymphoStat B belimumab 64 TOLAMBA 64 Dyloject TM 64 Manja Bouman CEO 64 randomized multicentre 64 proteasome inhibitor 64 ORENCIA ® 64 Zybrestat 64 BARACLUDE R 64 novel peptide 64 Preclinical Data 64 radiation sensitizer 64 cannabinor 64 photoprotective drug 64 BIBW 64 CCX# 64 Delcath Phase III 64 2 inhibitor CYT# 64 tolerability pharmacokinetics 64 Vion Pharmaceuticals 64 Evoltra ® 64 topoisomerase II inhibitor 64 humanised monoclonal antibody 64 HIV integrase inhibitor 64 Xcytrin R 64 Perifosine 64 ISTODAX 64 TRISENOX 64 generation Hsp# inhibitor 64 CCR5 mAb 64 TRACON Pharmaceuticals 64 Prodarsan R 64 PROVENGE ® 64 Sulonex TM 64 CCR9 antagonist 64 Tezampanel 64 LEP ETU 64 inhibitor RG# 64 Cimzia ® certolizumab pegol 64 R#/MEM 64 papillary renal cell carcinoma 64 GRN#L